Tuesday, 2 February 2021

Nanobiosensors in Healthcare Market To Observe Significant Growth By 2024

 Global Nanobiosensors in Healthcare Market is expected to register a CAGR of 9.84% from 2019 to 2024.

Nanotechnology in the biosensor is known as nanobiosensor; biosensors are analytical devices used for detection of chemical and biological substances in the human body. Nanobiosensors are the sensors that are made up of nanomaterials and have dimensions between 1 to 100 nanometers. Nanobiosensors are becoming popular in developed countries. The rising prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and raising awareness about advance nanobiosensors are expected to drive the growth of the market. According to the International Diabetes Federation (IDF), it is estimated that the number of diabetic patients in the Middle East and North Africa (MENA) region will grow by 96% from the year 2013 to 2035, i.e., from 34.6 million to 67.9 million. Moreover, rising R&D spending and collaborative strategies adopted by the top players, such as new product launches and collaborations for product development are contributing to the growth of the market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7993

The rising cost of nanobiosensors and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.

Nanobiosensors in Healthcare Market Segmentation

The global nanobiosensors in the healthcare market has been segmented on the basis of type, application, end user, and region.

On the basis of type, the market has been classified as optical nanobiosensors, electrochemical nanobiosensors, acoustic nanobiosensors, and others. Based on the application, the market has been segmented into diabetes, immunoassay, cancer, pathogenic bacteria, and others. The market, by end user, has been classified as hospitals and clinics, diagnostic centers, point of care, and others. The electrochemical nanobiosensors segment is expected to hold the largest market share of the nanobiosensors in healthcare market owing to its high sensitivity and real-time detection features. However, based on end user point of care testing segment holds the largest market share due to low complex infrastructure and training.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The nanobiosensors in the healthcare market in the Americas has further been segmented into North America and South America, with the North America market further divided into the US and Canada.

The European nanobiosensors in the healthcare market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The nanobiosensors in healthcare market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The nanobiosensors in healthcare market in the Middle East & Africa has been segmented into the Middle East and Africa.

Nanobiosensors in Healthcare Market Key Players

Some of the key players in the global nanobiosensors in healthcare market are Abbott Point of Care, Inc., F. Hoffman-LA Roche Ltd., Medtronic Inc., Nano-Proprietary, Inc., Lifescan, Inc., Illuminex Corporation, Lifesensors, Inc., ACON Laboratories, Inc., Pharmaco-Kinesis Corporation, Bayer Healthcare AG, Bio-Rad Laboratories, Inc., Biosensors International Pte. Ltd., Sysmex Corporation.

Regional Market Summary

The Americas are likely to dominate the global nanobiosensors in healthcare market owing to the rising prevalence of chronic disorders, initiative by government and regulatory authorities, and demands for advanced technology. According to the report published by the US Department of Health & Human Services, in 2017, around 11.5% of the adult population in the US are diagnosed with heart disease, i.e., 28.2 million.

The European market is expected to be the second largest nanobiosensors in healthcare market. The market growth in this region can be attributed to the government focus to control chronic disease, well-established healthcare infrastructure, and the rising population suffering from cardiovascular disorders. Moreover, government funding and support to the healthcare sector are also expected to boost the growth of the nanobiosensors in healthcare market during the forecast period. According to the European Heart Network, cardiovascular disorders are responsible for 3.9 million deaths in the European Union, which are 45% of the total deaths.

Asia-Pacific is expected to be the fastest-growing nanobiosensors in healthcare market during the forecast period owing to rising diabetes, increasing disposable income, and government initiatives for the development of the healthcare sector. According to the International Diabetes Federation, in 2017, more than 84 million people in South-East Asia were affected by diabetes, and this number is expected to reach 156 million by 2045. Moreover, the government of these countries is open to adopting new technology and the best treatment option from a developed country. According to the International Agency for Research on Cancer, in 2018, India has a prevalence of 173.5 cancer patients per 100,000 population. Moreover, in China, the prevalence rate of cancer was 377.6 patients per 100,000 population in 2018

The market in the Middle East & Africa is expected to hold the smallest share of the global nanobiosensors market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nanobiosensors-in-healthcare-market-7993


Radiology Services Market, Segments, Growth And Value Chain Analysis 2024

 The global radiology services market accounted for USD 8,102.51 million in 2018 and is expected to register a CAGR of 10.5% during the forecast period (2019–2024).

Radiology is the technology that diagnosis and treat diseases within the human body by using medical imaging. The radiology services are served by the radiologists and experts that are qualified for performing the test and have unique postgraduate medical education in, radiation effects on the human body, radiation safety/protection, appropriate performance and interpretation of quality radiologic, and medical imaging examinations. Radiology services comprise X-Rays, computed tomography (CT), ultrasound, fusion imaging, positron emission tomography (PET), nuclear medicine, and magnetic resonance imaging (MRI). These imaging techniques should be performed after having adequate training and understanding of radiation safety and protection.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7904

The rising prevalence of the chronic disease, increasing healthcare expenditure, the emergence of thin client 3D viewers, advancement in radiology technology, rising demand for minimally invasive procedures are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players, such as new product launches, are contributing to the growth of the market. For instance, In June 2018, FDA has anticipated reclassifying some types of radiology image software analyzers from class III to class II devices for mammography breast cancer, ultrasound breast lesions, and radiograph lung nodules. This will help to reduce the regulatory burden on the medical device industry.

However, the risk of high radiation exposure associated with the devices may hamper the growth of the market during the assessment period.

Segmentation

The global radiology services market has been segmented on the basis of product type, application, technology, end user, and region.

On the basis of product type, the market has been classified as stationary digital radiology systems and portable digital radiology systems. Stationary digital radiology systems have been further segmented into stationary ceiling-mounted systems and floor-to-ceiling mounted system. Based on application, the market has been segmented into cardiovascular imaging, chest imaging, dental imaging, mammography imaging, orthopedic imaging, and others. The market, by technology, has been segmented into computed radiology and direct digital radiology. On the basis of end user, the market has been classified as hospitals, diagnostic centers, and others. The stationary digital radiology segment is expected to hold the largest market share of the radiology services market due to acceptance of stationary systems in hospitals, extensive application, and less exposure to radiation. However, portable digital radiology segment is showing the highest growth rate owing to simplicity in the workflow, low-cost, and proficiency performing complex computational tasks.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The radiology services market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European radiology services market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The radiology services market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The radiology services market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

Some of the key players in the global radiology services market are 4ways Healthcare Limited, Cybernet Medical Corporation, Everlight Radiology, Global Diagnostics, Medica Reporting Ltd., Onrad, Inc, Radisphere National Radiology Group Inc., RamSoft Inc., Siemens Healthcare, Telediagnostics Services Pvt. Ltd., Telemedicine Clinic, Teleradiology Solutions Inc, and Virtual Radiology (vRAD).

Healthcare Analytics Market To Observe Strong Development By 2024

 Global healthcare analytics market size is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 12,126.70 million in 2018 and is projected to grow at a CAGR of 27.1% over the forecast period. Healthcare analytics is one of the major segment of analysis that primarily focuses on providing insights into hospital management, costs, patient records, diagnoses, and various other data. The field covers all the segments of the healthcare industry, providing insights on both the macro and micro level. The global healthcare/medical analytics market growth is expected to grow at a rapid pace due to factors such as high adoption of technological advancements in the field of healthcare, increasing demand for reducing paperwork, better treatment plans in collaboration with pharmaceutical organizations, increasing availability of low cost technology, to improve patient care efforts, better services, and improve existing procedures.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7819

For improve, treatment plans in association with pharmaceutical organizations are one of the major factors for analytics-driven revolution in healthcare. With more access to wide and in-depth information, pharmaceutical organizations can come up with better formulations for diseases. With the help of more data and analytics, pharmaceutical organizations will be able to assure their formulations positively. This will eventually move the trend from volume discounts to evidence-based outcome models. However, with these advantages of healthcare analytics driving the growth of the market, few restraints are hampering the growth of the market including; data security, high cost of analytical solutions, and technology challenged the user.   

Healthcare Analytics Market Segmentation

The global healthcare/medical analytics market has been segmented into type, component, delivery model, application and end user.

Based on type, market segmented into descriptive analytics, predictive analytics, prescriptive analytics, and cognitive analytics.

Based on component, market segmented into software, hardware, and services.

Based on delivery mode, market segmented into on-premise and on-demand.

Based on application, the healthcare/medical analytics market is segmented into Financial Analytics (Claims Processing, Revenue Cycle Management (RCM), Payment Integrity & Fraud, Waste, and Abuse (FWA), Risk Adjustment & Assessment), Clinical Analytics (Quality Improvement & Clinical Benchmarking, Clinical Decision Support (CDS)), operational & administrative analytics, population health analytics

Based on end user, healthcare analytics market segmented into Payers (Private Insurance Companies, Government Agencies, Employers and Private Exchanges), Providers (Hospitals & Clinics, Post-Acute Care Organizations, Ambulatory Settings), Others.

The global healthcare analytics market by region has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Healthcare Analytics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European Healthcare Analytics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The Healthcare Analytics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Healthcare Analytics market in the Middle East & Africa has been segmented into the Middle East and Africa.

 Healthcare Analytics Market Key players

Some of the prominent players in the global Healthcare/Medical Analytics market are Cerner, Allscripts Healthcare Solutions, SAS Institute Inc., IBM, Wipro, Inovalon, Cotiviti, Citiustech, Health Catalyst, Mckesson, Optum, Oracle, SCIO Health Analytics, Vitreoshealth, Medeanalytics, Others.

Current And Forthcoming Stethoscope Market Size In Terms Of Volume And Value 2024

 The global stethoscope market is expected to grow significantly over the forecast period. It is estimated that the global stethoscope market is expected to register a CAGR ~ 4.6% during the forecast period of 2019 to 2024 with an estimated market value of USD 332.1 million in 2018.

The global market is driven by factors such as increasing incidence rate of life-threatening diseases, increased spending on healthcare and ongoing research and development. Moreover, growing technological advancements such as Bluetooth connectivity with digital wireless hearing aids is expected to fuel the growth of the market during the assessment period. Furthermore, increasing innovations in the field of healthcare have pushed for the growth of the market. For instance, in October 2018, researchers from Rochester Institute of Technology and University of Rochester Medical Center developed a new electronic stethoscope that combines precision sensors, electrocardiogram technology, and machine learning applications into one piece of equipment to better detect heart ailments and problems that might occur with an implanted heart pump. Similarly, in March 2018, Neurologists from Stanford University developed brain stethoscope that can translate the brain’s activity into sounds so that silent seizures can be detected. On the other hand, poor healthcare system and less access to health services in certain economies are restraining the growth of stethoscope market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7802

Moreover, major companies in the market are involved in strategic collaborations to brace their position in the market. For instance, in September 2015, eKuore launched its first wireless stethoscope in Düsseldorf, Germany. 

Segmentation

The global stethoscope market has been segmented into type, and end user. The market, based on type, has been segmented into manual stethoscope and electronic stethoscope. The market, by manual stethoscope, has been further segmented into a fetal stethoscope, and others. The market, by electronic stethoscope, has been sub-segmented into esophageal stethoscopes, fetal heart rate detectors, and others. The market, by end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. Hospitals are expected to hold a major share in the end user segment owing to the increased occurrences of diseases, as well as the rise in the patient visits. Clinics are projected to be the fastest growing segment due to the ease of accessibility it provides to the patients.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The stethoscope market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European stethoscope market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The stethoscope market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The stethoscope market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

3M, A&D Medical, American Diagnostic Corporation, Cardionics, GF Health Products, Heine Optotechnik, McCoy Medical, Medline Industries, Omron Corporation, Rudolf Riester, Smith’s Medical, and Welch Allyn are some of the key players in the global stethoscope market.

Regional Market Summary

Geographically, the Americas is expected to dominate the global stethoscope market due to the increasing per capita healthcare expenditure. The rise in product innovation and the heavy adoption of new technology is anticipated to drive the growth of the market.

Europe showed a considerable amount of growth in the global stethoscope market. The market growth in this region is because of the presence of a well-established healthcare system. The rise in the patient population is also contributing to the growth in the region.

Asia-Pacific is estimated to be the fastest growing region in the market due to a rise in the number of health welfare programs. This growing awareness in Asian countries by public and private organizations is projected to fuel the growth of the market during the assessment period. On the other hand, the Middle East & Africa has the least share of the market due to the low disposable income.

Hepatitis B Treatment Market To Observe Strong Development By 2024

 The global hepatitis B treatment market is expected to register an approximate CAGR of 5.3% during the forecast period, i.e., from 2018 to 2024.

Hepatitis is a viral infection caused by Hepatitis A, B or C virus. The infection results to cause liver infection or inflammation and many times leading to liver damage.

Hepatitis B virus spreads through coming in contact with infected blood, drinking contaminated water, and using infected needles or syringes.  The person suffering from Hepatitis B faces various symptoms such as poor appetite, weakness, jaundice, dark-colored urine, itching on skin, swelling on legs, weight loss, drowsiness and many more. According to the World Health Organization 2018 fact sheet, it was estimated that 257 million people across the world have lived with hepatitis B infection and also mentioned that around 887,000 number of people died from hepatitis B in 2015. Thus, the increasing prevalence of Hepatitis B across the world boosts market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7817

However, the factors such as side effects associated with treatment and medications hinder the market growth.

Hepatitis B Treatment Market Segmentation

 

The global hepatitis B treatment market is segmented on the basis of type, treatment, distribution channel, and region.

Based on type, the market is segmented into acute and chronic. On the basis of treatment, the global hepatitis B treatment market is segmented into immune modulator drugs, antiviral drugs, vaccine, and surgery  (liver transplant). The immune modulator drugs are further sub-segmented into pegylated interferon and interferon alpha. The antiviral drugs are sub-segmented into tenofovir disoproxil, entecavir, telbivudine, lamivudine, and others. By distribution channel, the market is segmented into hospital & retail pharmacies and online pharmacies.

Based on region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Hepatitis B Treatment Market Key players

 

Some of the key players in the global hepatitis B treatment market are Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Par Pharmaceutical, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Others.

Hepatitis B Treatment Regional Market Summary

Sources: Centers for Disease Control and Prevention, GOV.UK, Society of Cardiovascular Computed Tomography, Indian Brand Equity Foundation, Annual Reports, Press Release, White Paper, And Company Presentation

The Americas dominates the global market for hepatitis B treatment owing to the increasing bacterial infection, development in the clinical practices, and availability and access of best treatments for viral infection in this region.

Moreover, high healthcare expenditure within the Americas boosts the regional market. According to the National Vaccine Information Center, there were 3,370 acute cases of hepatitis B in the US in 2015. Following similar trends, Europe stood second in the global hepatitis B treatment market. On a regional basis, the European market is segmented into Western Europe and Eastern Europe. Europe is estimated to lead the market due to the presence of advanced medical facilities and rising viral infection among the population contributes to increasing the new cases of hepatitis B among the population. According to the World Health Organization data sheet, hepatitis B and C affects a large number of people in the European region. It also, stats that globally, 1.5 million people die every year because of hepatitis B virus. The increasing incidences of hepatitis B in Europe boost market growth.

Asia Pacific is estimated to be the fastest growing region for the global hepatitis B treatment market in 2017. A rapidly growing medical diagnostic sector, growing prevalence of bacterial infection and a large number of patients suffering from HIV infection support market growth.

On the other hand, the Middle East and Africa hold the least share in the global hepatitis B treatment market owing to stringent government policies, presence of poor economies, lack of awareness, and low healthcare expenditure within the region.

Orthobiologics Market To Observe Significant Growth By 2024

 The Global Orthobiologics Market is accounted for USD 4,964 million in 2019 and expected to register 5.6% CAGR during the forecast period (2019–2024).

Orthobiologics are substances that are used by orthopedic surgeons to heal injuries more quickly. The orthobiologics are used to improve the tendons, ligaments, healing of broken bones and injured muscles. Also, these products are derived from substances that are naturally found in the body. When they are used in higher concentrations, orthobiologic substances help speed up the healing process.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7826

The increasing cases of trauma and sports injury, demand for biologics in minimally invasive procedures, approval of products, and raising awareness are expected to drive the growth of the global orthobiologics market during the forecast period. Moreover, emerging technological innovations in biomaterials, rising obese and geriatric population, and rising research and development activities by top players such as mergers, expansion, and collaboration for the development of new products and launches by major players are also boosting the growth of the market. For instance, according to the data provided by U.S. Department of Commerce, in 2015, the total population above the age 60 was around 902.28 million, whereas, in 2018, the total population above the age of 60 are around 991.24 million. The population above 60’s year are growing with a rate of 3.18% per years.

However, less reimbursement policy may hamper the growth of the market during the assessment period.

Orthobiologics Market Segmentation

 

The global orthobiologics market has been segmented on the basis of product, application, end-user, and region.

On the basis of product, the market has been classified as a Demineralized bone matrix (DBM), Bone morphogenetic protein (BPM), Allograft, Viscosupplementation products, Synthetic bone substitutes, and Others.

Based on application, the market has been divided into Osteoarthritis & degenerative arthritis, Spinal fusion, Fracture recovery, Soft tissue injuries, and Others. By application spinal fusion segment dominant, the market in 2018 due to increasing sports-related injuries, the prevalence of spine and traumatic injuries, and accidents.

By end user, the market has been segmented into Hospitals, Orthopedic Clinics, and Others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The orthobiologics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European orthobiologics market has been segmented into Western Europe and Eastern Europe. Western Europe has been sub-segmented into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The orthobiologics market in Asia-Pacific has been divided into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The orthobiologics market in the Middle East & Africa has been segmented into the Middle East and Africa.

Top Trends In Drug Discovery Informatics Market By 2023

 Global drug discovery informatics market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 1,680.6 million in 2017 and is projected to grow at a CAGR of 11.5% during the forecast period. Drug discovery and development is a highly intricate process requiring the generation of very large amounts of data and information. Large amounts of data are generated using a variety of innovative technologies, and the limiting step is accessing, searching and integrating this data. The current approaches to collect information from various sources have been dealt with in some cases where the data types are very least well-defined or largely homogeneous. However, the world is on the verge of a new age of drug discovery informatics, the methods and approaches in which are dealing with gathering information from data and knowledge from information are undergoing a paradigm shift. Mining and integration of domain-specific information such as chemical and genomic data will continue to develop in the near future.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/7831

Drug discovery is a functional process in pharmaceutical and biotechnology companies. It involves different steps and procedures that depend on in-silico tools for reducing the complexity of a process. Some of the factors driving the market growth are a rising worldwide focus on drug discovery, growing need to control drug discovery and development costs, growth in R&D expenditure, and increasing burden of chronic diseases. For instance, according to the World Health Organization (WHO), in 2001, chronic diseases contributed around 60% of the 56.5 million total reported deaths across the world and approximately 46% of the global burden of disease, which is projected that, by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide. On the other hand, high pricing and setup cost of informatics software is anticipated to restrict the market growth during the forecast period.

Segmentation

The global drug discovery informatics market has been segmented into product, mode, service, end user, and region.

By product, the market has been segmented into discovery informatics and development informatics.

On the basis of mode, the market has been divided into in-house informatics and outsourced informatics.

By service, the market has been classified into sequencing and target data analysis, docking, molecular modeling, clinical trial data management, and others. The sequencing and target data analysis segment is expected to dominate the market over the forecast period due to rising application of informatics solutions in targeted analysis and a large amount of data generated during the drug discovery process.

Based on end user, the market has been categorized into pharmaceutical and biotechnology industries, contract research organizations (CROs), and others.

The global drug discovery informatics market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The drug discovery informatics market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.

The European drug discovery informatics market has been segmented into Western Europe and Eastern Europe. The Western Europe drug discovery informatics market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The drug discovery informatics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The drug discovery informatics market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Few of the spearheads in the global drug discovery informatics market are Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery Inc., Selvita, Charles River Laboratories, Inc., International Business Machines Corporation, Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, and Dassault Systèmes.